The therapeutic benefits of a garden environment have been documented since ancient times, according to the American Horticultural Therapy Association, but it’s something many of us know ...

A panelist discusses how ASCO 2025's most important breakthrough was the oral decitabine plus venetoclax combination, representing a potential paradigm shift if approved by the FDA, while highlighting ...

It wasn’t long ago that the outcome facing many patients with Stage 3 non-small cell lung cancer (NSCLC) was bleak. An estimated 43,000 Americans are diagnosed each year with Stage 3 NSCLC ...

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse NANTES, France, June 12 ...

On February 5, 2024, a new research paper was published in Oncotarget, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and ...

A New Approval in the PrEP Therapeutic Landscape. Frank J. Palella, Jr discusses cabotegravir, a recently approved injectable PrEP medication, that was test in the HTPN 083 and -084 trials.

Immunotherapy Active as First-Line Therapy. KEYNOTE-025 with pembrolizumab was the first study of immunotherapy as first-line therapy. It was conducted in patients metastatic or locally advanced ...

Despite great strides made in the treatment of non-small cell lung cancer (NSCLC) over the past decade with the advent of new and improved regimens with chemotherapy, radiotherapy, and surgery ...